All Articles

PNC's revamped mobile app offers slick customization, but its real story is the AI-ready architecture underneath—a blueprint for the future of finance.

After 32 years, Edward Duffy's $608M team leaves Commonwealth post-LPL deal, choosing Cetera's model of flexibility and direct leadership access.

Overland Park's Aspyre Wealth Partners is expanding its team and office. Can it navigate the industry's biggest challenge: growing big while keeping service small?

Montreal's Salutt Inc. launches Ready to Date, betting its 'Love Compass' can fix a broken dating scene. But can it overcome the user density paradox?

OZ Digital's new partnership with Anthropic isn't just another deal. It's a strategic move empowering enterprises to escape the one-size-fits-all AI trap.

As unaddressed grief costs billions, Pathpal's proactive platform just secured a major investment to scale its 'grieftech' solution for the modern workplace.

A tedious but critical step in drug discovery is getting a major upgrade. Unchained Labs' Lil' Tuna automates buffer exchange, a key bottleneck, signaling a larger shift toward compact, AI-integrated labs.

Sketchy's AI platform, a CODiE finalist, signals a shift in medical training. It uses virtual patients to bridge the gap between classroom theory and clinical reality.

VR Resources' deep drill at New Boston validates advanced geophysics, revealing a vast polymetallic system vital for North American resource independence.

Three aviation giants are betting they can solve the dreaded 100-mile journey. Their plan? A network of quiet, hybrid planes to bypass traffic and reconnect towns.

Keiko Fujimori's narrow victory in Peru signals a major policy shift, potentially fast-tracking key lithium and uranium projects for the global tech supply chain.

A new Shopify integration by Payfuture aims to solve a critical puzzle for global e-commerce: accepting local payments like UPI in India's booming market.

As OKYO Pharma woos investors with a promising eye drug, it carries the hopes of patients with debilitating pain. A look at the science, stakes, and systems.

With a major FDA decision pending, Aquestive Therapeutics pitches its game-changing anaphylaxis film, Anaphylm, to Wall Street's top healthcare investors.

In two months, one company has become the dominant home care force in Newfoundland. This isn't just business; it's a blueprint for the future of elder care.

Bollinger Shipyards' multi-year commitment to CGMA is more than charity; it's a savvy investment in the human capital that underpins national security.

The FDA has fast-tracked mitapivat for sickle cell disease, offering new hope for patients. But a closer look reveals the high stakes of this strategy.

HMNC Brain Health's new oral ketamine shows promise by minimizing side effects, but an unmet endpoint raises questions. Is this the key to at-home TRD care?

With an $85M commitment, Dundee Corp. is fast-tracking a massive exploration and drilling program at Westhaven's Spences Bridge Gold Belt properties.

Saol Therapeutics' NDA resubmission isn't just a second chance; it's a calculated maneuver signaling a new playbook for navigating the FDA in rare disease.